Jan Elsner

Optimization of a Series of Triazole Containing Mammalian Target of Rapamycin (mTOR) Kinase Inhibitors and the Discovery of CC-115

Deborah S. Mortensen, Sophie Perrin-Ninkovic, Graziella Shevlin et al. · Journal of Medicinal Chemistry · 2015 · 72 citations · Full text

Drug Target, Kinase Inhibitors, Pharmacotherapy +16

Highly Potent 5-Aminotetrahydropyrazolopyridines: Enantioselective Dopamine D₃Receptor Binding, Functional Selectivity, and Analysis of Receptor−Ligand Interactions

Nuška Tschammer, Jan Elsner, Angela Goetz et al. · Journal of Medicinal Chemistry · 2011 · 61 citations · Full text

The Discovery of a Dual TTK Protein Kinase/CDC2-Like Kinase (CLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer Initiated from a Phenotypic Screen

Jennifer R. Riggs, Mark A. Nagy, Jan Elsner et al. · Journal of Medicinal Chemistry · 2017 · 59 citations · Full text

Breast Oncology, Pharmaceutical Chemistry, Tumor Biology +18

Pharmacophore-Guided Drug Discovery Investigations Leading to Bioactive 5-Aminotetrahydropyrazolopyridines. Implications for the Binding Mode of Heterocyclic Dopamine D3 Receptor Agonists

Jan Elsner, Frank M. Boeckler, Frank W. Heinemann et al. · Journal of Medicinal Chemistry · 2005 · 41 citations · Full text

Drug Target, Binding Affinity, Pharmacotherapy +17

Discovery of the c-Jun N-Terminal Kinase Inhibitor <b>CC-90001</b>

Mark A. Nagy, Robert Hilgraf, Deborah S. Mortensen et al. · Journal of Medicinal Chemistry · 2021 · 35 citations · Full text